Analyst Price Target is $5.60
▲ +0.18% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for BioDelivery Sciences International in the last 3 months. The average price target is $5.60, with a high forecast of $5.60 and a low forecast of $5.60. The average price target represents a 0.18% upside from the last price of $5.59.
Current Consensus is
The current consensus among 4 contributing investment analysts is to hold stock in BioDelivery Sciences International. This rating has held steady since February 2022, when it changed from a Buy consensus rating.
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.